These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9925292)

  • 1. The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ET(B) receptor.
    Chan MF; Kois A; Verner EJ; Raju BG; Castillo RS; Wu C; Okun I; Stavros FD; Balaji VN
    Bioorg Med Chem; 1998 Dec; 6(12):2301-16. PubMed ID: 9925292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).
    Murugesan N; Gu Z; Stein PD; Bisaha S; Spergel S; Girotra R; Lee VG; Lloyd J; Misra RN; Schmidt J; Mathur A; Stratton L; Kelly YF; Bird E; Waldron T; Liu EC; Zhang R; Lee H; Serafino R; Abboa-Offei B; Mathers P; Giancarli M; Seymour AA; Webb ML; Hunt JT
    J Med Chem; 1998 Dec; 41(26):5198-218. PubMed ID: 9857090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.
    Murugesan N; Tellew JE; Gu Z; Kunst BL; Fadnis L; Cornelius LA; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Panchal B; Valentine MT; Chong S; Morrison RA; Carlson KE; Powell JR; Moreland S; Barrish JC; Kowala MC; Macor JE
    J Med Chem; 2002 Aug; 45(18):3829-35. PubMed ID: 12190306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
    Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
    Kanda Y; Takahashi T; Araki Y; Konoike T; Mihara S; Fujimoto M
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1875-8. PubMed ID: 10969989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.
    Wu C; Chan MF; Stavros F; Raju B; Okun I; Mong S; Keller KM; Brock T; Kogan TP; Dixon RA
    J Med Chem; 1997 May; 40(11):1690-7. PubMed ID: 9171878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.
    Ksander GM; Shetty SS; DelGrande D; Balwierczak JL; Bruseo CW; Savage P; deJesus R; Yuan A; Webb RL; Jeng AY
    Can J Physiol Pharmacol; 2002 May; 80(5):464-9. PubMed ID: 12056554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
    Stein PD; Floyd DM; Bisaha S; Dickey J; Girotra RN; Gougoutas JZ; Kozlowski M; Lee VG; Liu EC; Malley MF
    J Med Chem; 1995 Apr; 38(8):1344-54. PubMed ID: 7731020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists.
    Kanda Y; Kawanishi Y; Oda K; Sakata T; Mihara SI; Asakura K; Kanemasa T; Ninomiya M; Fujimoto M; Konoike T
    Bioorg Med Chem; 2001 Apr; 9(4):897-907. PubMed ID: 11354672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
    Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid peptides constructed from RES-701-1, an endothelin B receptor antagonist, and endothelin; binding selectivity for endothelin receptors and their pharmacological activity.
    Shibata K; Suzawa T; Ohno T; Yamada K; Tanaka T; Tsukuda E; Matsuda Y; Yamasaki M
    Bioorg Med Chem; 1998 Dec; 6(12):2459-67. PubMed ID: 9925302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of IRL 3461: a novel and potent endothelin antagonist with balanced ETA/ETB affinity.
    Sakaki J; Murata T; Yuumoto Y; Nakamura I; Trueh T; Pitterna T; Iwasaki G; Oda K; Yamamura T; Hayakawa K
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2241-6. PubMed ID: 9873521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
    Wu C; Chan MF; Stavros F; Raju B; Okun I; Castillo RS
    J Med Chem; 1997 May; 40(11):1682-9. PubMed ID: 9171877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin ET
    Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
    Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist.
    Wu C; Decker ER; Blok N; Li J; Bourgoyne AR; Bui H; Keller KM; Knowles V; Li W; Stavros FD; Holland GW; Brock TA; Dixon RA
    J Med Chem; 2001 Apr; 44(8):1211-6. PubMed ID: 11312921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity.
    Fukami T; Yamakawa T; Niiyama K; Kojima H; Amano Y; Kanda F; Ozaki S; Fukuroda T; Ihara M; Yano M; Ishikawa K
    J Med Chem; 1996 Jun; 39(12):2313-30. PubMed ID: 8691426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.
    Seo B; Oemar BS; Siebenmann R; von Segesser L; Lüscher TF
    Circulation; 1994 Mar; 89(3):1203-8. PubMed ID: 8124808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of a novel endothelin receptor that binds both ETA- and ETB-selective ligands.
    Nambi P; Pullen M; Kincaid J; Nuthulaganti P; Aiyar N; Brooks DP; Gellai M; Kumar C
    Mol Pharmacol; 1997 Oct; 52(4):582-9. PubMed ID: 9380020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.